Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 192

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Adverse Outcomes of Tacrolimus Withdrawal in Immune–Quiescent Kidney Transplant Recipients

Open access
Hricik, Donald E., Formica, Richard N., Nickerson, Peter, Rush, David, Fairchild, Robert L., Poggio, Emilio D., Gibson, Ian W., Wiebe, Chris, Tinckam, Kathryn, Bunnapradist, Suphamai, Samaniego-Picota, Milagros, Brennan, Daniel C., Schröppel, Bernd, Gaber, Osama, Armstrong, Brian, Ikle, David, Diop, Helena, Bridges, Nancy D., Heeger, Peter S. · 2015 · Journal of the American Society of Nephrology

Abstract

Concerns about adverse effects of calcineurin inhibitors (CNIs) have prompted development of protocols that minimize their use. Whereas previous CNI withdrawal trials in heterogeneous cohorts showed unacceptable rates of acute rejection (AR), we hypothesized that we could identify individuals capable of tolerating CNI withdrawal by targeting immunologically quiescent kidney transplant recipients. The Clinical Trials in Organ Transplantation-09 Trial was a randomized, prospective study of nonsensitized primary recipients of living donor kidney transplants. Subjects received rabbit antithymocyte globulin, tacrolimus, mycophenolate mofetil, and prednisone. Six months post-transplantation, subjects without de novo donor-specific antibodies (DSAs), AR, or inflammation at protocol biopsy were randomized to wean off or remain on tacrolimus. The intended primary end point was the change in interstitial fibrosis/tubular atrophy score between implantation and 24-month protocol biopsies. Serially collected urine CXCL9 ELISA results were correlated with outcomes. The study was terminated prematurely because of unacceptable rates of AR (4 of 14) and/or de novo DSAs (5 of 14) in the tacrolimus withdrawal arm. Positive urinary CXCL9 predated clinical detection of AR by a median of 15 days. Analyses showed that >16 HLA-DQ epitope mismatches and pretransplant, peripheral blood, donor-reactive IFN-γ ELISPOT assay results correlated with development of DSAs and/or AR on tacrolimus withdrawal. Although data indicate that urinary CXCL9 monitoring, epitope mismatches, and ELISPOT assays are potentially informative, complete CNI withdrawal must be strongly discouraged in kidney transplant recipients who are receiving standard-of-care immunosuppression, including those who are deemed to be immunologically quiescent on the basis of current clinical and laboratory criteria.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2014121234

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 192

Metadata

Authors
Hricik, D. E., Formica, R. N., Nickerson, P., Rush, D., Fairchild, R. L., Poggio, E. D., Gibson, I. W., Wiebe, C., Tinckam, K., Bunnapradist, S., Samaniego-Picota, M., Brennan, D. C., Schröppel, B., Gaber, O., Armstrong, B., Ikle, D., Diop, H., Bridges, N. D., & Heeger, P. S.
Venue
Journal of the American Society of Nephrology
Published
2015-12
Volume
26
Issue
12
Pages
3114-3122
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2103073605
Cited by
192
References
2
FWCI
18.75
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adverse Outcomes of Tacrolimus Withdrawal in Immune–Quiescent Kidney Transplant Recipients. https://app.cochat.ai/papers/10.1681/asn.2014121234
The paper
Hricik, D. E., Formica, R. N., Nickerson, P., Rush, D., Fairchild, R. L., Poggio, E. D., Gibson, I. W., Wiebe, C., Tinckam, K., Bunnapradist, S., Samaniego-Picota, M., Brennan, D. C., Schröppel, B., Gaber, O., Armstrong, B., Ikle, D., Diop, H., Bridges, N. D., & Heeger, P. S. (2015). Adverse Outcomes of Tacrolimus Withdrawal in Immune–Quiescent Kidney Transplant Recipients. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2014121234

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.